NIAID Site Search

Product Development Plan (PDP) for a Generic Prophylactic Vaccine for Infectious Diseases

Last Reviewed: September 30, 2023

Last Reviewed: March 31, 2025

An overview of the history of Black Mountain (RML) and early research contributions from NIAID

Last Reviewed: August 16, 2023

Sample grant application from Stephen Dewhurst, Ph.D., for exploratory with possible transition to expanded development grant (R21/R33).

Last Reviewed: April 21, 2025

Generic Preclinical Development Plan for Human Monoclonal Antibodies

Last Reviewed: August 1, 2024

Stephen Dewhurst, Ph.D., of the University of Rochester, R21/R33 sample application

Last Reviewed: March 31, 2025

Lenette Lu, M.D., Ph.D., of the Massachusetts General Hospital K08 sample application

Last Reviewed: March 31, 2025

Efforts to develop safe and effective vaccines increasingly involve the use of adjuvants—substances formulated as part of a vaccine to boost immune responses and enhance the vaccine’s effectiveness. NIAID plays a leading role in the discovery, development, and characterization of new vaccine adjuvants. Why is the Study of Vaccine Adjuvants a Priority for NIAID? Researchers can use adjuvants to

Last Reviewed: May 10, 2022

Program Leadership Christa S. Zerbe, M.D., MS Director, Infectious Disease Fellowship Program Medical Director, Clinical Patient Services Unit LCIM Senior Staff Clinician More about Dr. Zerbe Veronique Nussenblatt, M.D., Sc.M., M.H.S. Chief, Infectious Disease Consult Service Associate Program Director, Infectious Diseases Fellowship Director, NIH Residency Electives Program (REP) and Clinical

Last Reviewed: December 8, 2022

NIH study 17-I-0122 offered genetic testing called genome sequencing. Some people who joined this study got results that did not find a genetic cause for their symptoms. Find out what these results mean.

Last Reviewed: May 23, 2023

Guidelines for Diagnosis and Management of Food Allergy in the United States from the NIAID-Sponsored Expert Panel.

Last Reviewed: October 24, 2018

NIH study 17-I-0122 offered genetic testing called genome sequencing. Some people who joined this study got results that did not find a genetic cause for their symptoms. Find out what these results mean.

Last Reviewed: May 23, 2023

The postbac training experience is an important time for young scientists to develop the skills necessary for success in their future careers while contributing to NIAID mission research. A supportive mentor can help a postbac make the most of their fellowship as they navigate significant career decisions. Read reflections from postbac fellows on how being mentored by NIAID postdocs enhanced their training experience.

Published: April 28, 2023

NIAID welcomes entrepreneurs and small business leaders to explore grant and contract funding opportunities and engage in collaboration with NIAID.

Last Reviewed: March 19, 2025

The generic product development plans (PDPs) and target product profiles (TPPs) below provide guidance to support product development activities through Phase 1 clinical development: PDP for Human Monoclonal Antibodies PDP for Small Molecule Anti-infectives PDP for a Generic Prophylactic Vaccine for Infectious Diseases TPPs for Antivirals

Last Reviewed: April 17, 2025

James M. Cherry, Ph.D. Chief, Research Technologies Branch Dr. Jim Cherry obtained his Ph.D. from the Catholic University of America in molecular biology with a concentration in bio-medical science. He earned an M.S. from Johns Hopkins University in molecular biology with a concentration in biotechnology. His bachelor’s degree is from Shepherd University with a major in biology and minor in

Last Reviewed: August 31, 2022

NIAID offers a variety of individual research career development (K) awards, which enable scientists to enhance their careers in biomedical research.

Last Reviewed: March 18, 2025

NIAID uses the following programs to develop and support the next generation of biomedical researchers.

Last Reviewed: July 3, 2024

This brochure provides a reference guide for prescription HIV-1 medications including images and dosages.

Last Reviewed: June 3, 2024

NIAID Postbac Lila Berle, highlights four of the presentations from the the 2022 NIH Postbac Poster Days. The virtual platform emulated the experience of attending in-person presentations, as both trainees and judges bounced between rooms to visit the posters of NIH postbacs describing the research they've been working on all year.

Published: June 6, 2022

Rocky Mountain Laboratories in Hamilton, Montana is home to a thriving community of researchers who investigate some of the world's most challenging infectious disease threats. Read about how postbacs at RML contribute to this work and the different ways they get involved in their local communities.

Published: January 31, 2024

This DAIDS SCORE Manual provides an overview of clinical research investigator responsibilities and related references.

Last Reviewed: October 30, 2024

Senior Leadership for NIAID's Vaccine Research Center (VRC)

Last Reviewed: February 25, 2025

The Behavioral and Social Sciences Project Team (BSSPT) enhances the integration of behavioral and social sciences (BSS) into biomedical HIV clinical research, including clinical trials of HIV vaccines, non-vaccine prevention, therapeutics, and cure research.

Last Reviewed: May 10, 2022

Read about what it’s like to be a postbac in a malaria lab at NIAID. This article was written by Margaret Rose Smith, Postbac in the Malaria Immunology Section, Laboratory of Malaria & Vector Research, NIAID Division of Intramural Research, Twinbrook.

Published: September 21, 2020